Black Diamond Therapeutics
Market cap $82.8M 57.5M shares (10-Q, Nov 5, 2026) × $1.44 close Nov 17, 2026
Most recent annual filing: 2026-03-16
- BH-30643 BlossomHill FDA feedback4Q 2026BH-30643 BlossomHill FDA feedback, 4Q 2026, notable
- Silevertinib Ph2 start4Q 2026Silevertinib Ph2 start, 4Q 2026, routine
- Silevertinib EP opposition deadline~Dec 11, 2026Silevertinib EP opposition deadline, ~Dec 11, 2026, routine
- Black Diamond corporate China decisionDec 18, 2026Black Diamond corporate China decision, Dec 18, 2026, material
- Silevertinib GBM Ph2 interim1H 2028Silevertinib GBM Ph2 interim, 1H 2028, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
BDTX-4933
S241656BDTX-4876
- Undisclosed indication
Technology platforms
MAP · Revelio Therapeutics
Mutation-Allostery-Pharmacology (MAP) drug discovery engine used to identify and design MasterKey therapies targeting families of oncogenic mutations in cancer patients; licensed to Revelio Therapeutics for large molecule therapeutics discovery
MAP
Mutation Allostery Pharmacology (MAP) drug discovery engine — identifies oncogenic mutations across genes, confirms oncogenicity via cell and tumor models, and guides pharmacologic inhibition of mutant proteins while sparing wild-type; used to discover MasterKey inhibitors for genetically defined cancers including NSCLC and GBM
Capital (as filed)
- Cash
- $15.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $86.9M Sep 30, 2026
- Operating cash flow
- −$8.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $102M cash, runway second half of 2028 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-11 UPDATE: Black Diamond Therapeutics (BDTX) - The FDA Draws the Map, Nobody Pays the Fare 🔒 Paid
- 2026-10-08 Black Diamond Therapeutics (BDTX) - Scientific Deep Dive for Silevertinib and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Black Diamond Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-08 Watch Black Diamond Therapeutics (BDTX) - Scientific Deep Dive for Silevertinib and Pipeline Products Silevertinib has real CNS activity and is priced at cash, but lacks a funded pivotal trial, has afatinib-grade tolerability at the tested dose, and faces a competitor already ten months into a comparable Phase 3.
- 2026-11-11 Watch UPDATE: Black Diamond Therapeutics (BDTX) - The FDA Draws the Map, Nobody Pays the Fare FDA feedback was better than feared with a workable 300-patient brain-metastasis Phase 3 and accelerated-approval path, but the trial remains unfunded with no partner announced and the company has disclosed it needs substantial additional capital.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Company remains on track to initiate the randomized portion of the study in the fourth quarter of 2026.”
matched to Silevertinib · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (15)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 9, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseBlack Diamond Therapeutics to Participate in Upcoming Investor Conferences
- Nov 10, 2026ReleaseBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateBlack Diamond's October 1 FDA meeting produced a brain-metastases-enriched Phase 3 design with CNS-ORR as the accelerated approval endpoint — a narrower, potentially faster path than feared — but the stock sold off 14% because the partner who would fund it still doesn't exist.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 9, 2026ReleaseBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
- Aug 5, 20268-KCurrent report: results of operations · EX-99.1
- Aug 5, 202610-QQuarterly report
- Jun 29, 20268-KCurrent report: shareholder vote
- May 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 29, 2026DEFA14AProxy soliciting material
- Apr 29, 2026DEF 14AProxy statement
- Mar 16, 20268-KCurrent report: results of operations · EX-99.1
- Mar 16, 202610-KAnnual report
4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Jul 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 8, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026ARSAnnual report to shareholders
- Mar 16, 2026S-8Employee plan registration